Uncategorized

EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023

The 16th international Rare Disease Day is on the 28th of February, 2023. Rare Disease Day is the official international awareness-raising campaign for rare diseases. Rare Disease Day takes place on the last day of February each year. The main objective of the campaign is to raise awareness amongst the general public and decision-makers about …

EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023 Read More »

EffRx Attending the Annual Meeting SSEDP / SGPED on 26. January 2023 at the Universitäts-Kinderspital Zürich

The Swiss Society for Pediatric Endocrinology and Diabetology (SGPED) is composed of pediatric endocrinologists and individuals from allied health professions. Together with supporting sponsors like EffRx, the Society is jointly committed to improving the care of children and adolescents with endocrinological diseases and diabetes mellitus. For the second year in a row, EffRx will be …

EffRx Attending the Annual Meeting SSEDP / SGPED on 26. January 2023 at the Universitäts-Kinderspital Zürich Read More »

EffRx Attends the 1st Eastern Switzerland Symposium on Rare Diseases in St. Gallen, Switzerland

The Eastern Switzerland Symposium on Rare Diseases took place for the first time on November 24, 2022, and attracted a high number of participants from a broad range of disciplines. The motto of the conference, chaired by experts from the Cantonal Hospital St. Gallen and Eastern Switzerland Children’s Hospital, was “Learning from the Rare Diseases …

EffRx Attends the 1st Eastern Switzerland Symposium on Rare Diseases in St. Gallen, Switzerland Read More »

EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announces the launch of Alkindi® (hydrocortisone capsules for oral use) in Switzerland as replacement therapy for adrenal insufficiency in infants, children and adolescents (from birth to <18 years old). Alkindi® is the first approved pediatric-specific …

EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland Read More »

EffRx Attending the 9th I-DSD Symposium 2022 in Bern, Switzerland, University Hospital Bern from 14-16th July 2022

The International Symposium on the Differences & Disorders of Sex Development I-DSD has been very successful in attracting a rapidly expanding multidisciplinary group of experts, eager to discuss the latest advances in the field and have laid the foundation for fruitful international collaborations. In 2021, the I-DSD/I-CAH/I-TS has a network that reaches 260 centers in 63 …

EffRx Attending the 9th I-DSD Symposium 2022 in Bern, Switzerland, University Hospital Bern from 14-16th July 2022 Read More »

World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe

World Orphan Drug Alliance (WODA) is a new global alliance of full-service regional distributors for orphan drugs. WODA covers 68 countries on 4 continents. There are more than 64 million potential patients with rare diseases in the WODA regions. Zurich, Ljubljana, Moscow, Sao Paulo, Dubai, May 12, 2022 – EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC, and …

World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe Read More »

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland

FREIENBACH, Switzerland –-BUSINESS WIRE–-  EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as a treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms …

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland Read More »

EffRx Supports the 15th Annual Rare Disease Day on 28. February 2022

Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. Since its creation in 2008, Rare Disease Day has played a critical part in building an international rare disease community that is multi-disease, global, and …

EffRx Supports the 15th Annual Rare Disease Day on 28. February 2022 Read More »

Scroll to Top